2012 Projections Revised Downwards As Drug Reimbursement Act Finalised

BMI View: Late-stage revisions to Poland's pharmaceutical reimbursement act have been broadly positive for pharmaceutical companies operating in this market. However, the central premise of the legislation, which caps reimbursed pharmaceutical expenditure to 17% of healthcare budget, remains and is set to moderate drug expenditure growth in the coming years. Despite the latest legislation, BMI maintains its view that Poland is one of the more attractive pharmaceutical markets in Central and Eastern Europe (CEE).At the end of May 2011, Polish President Bronisław Komorowski signed the final version of the Drug Reimbursement Act after approving the modifications recommended by the senate. The legislation will take effect from January 01 2012.

To read the full article, please choose one of the following options: